1
|
Ye Q, Geng X, Jiang H, Qin C, Wu H, Wang S, Wen H. Genotoxicity assessments of N-nitrosoethylisopropylamine (NEIPA) and N-nitrosodiisopropylamine (NDIPA) in the C57BL/6J mouse. MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2024; 896:503763. [PMID: 38821676 DOI: 10.1016/j.mrgentox.2024.503763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/28/2024] [Revised: 04/26/2024] [Accepted: 04/27/2024] [Indexed: 06/02/2024]
Abstract
N-Nitrosamines, known as drug impurities and suspected carcinogens, have drawn significant public concern. In response to drug regulatory needs, the European Medicines Agency (EMA) has previously proposed a carcinogenic potency categorization approach based on the N-nitrosamine α-hydroxylation hypothesis, i.e., that N-nitrosamine mutagenicity increases with the number of α-hydrogen atoms. However, this structure-activity relationship has not been fully tested in vivo. NEIPA (N-nitrosoethylisopropylamine) and NDIPA (N-nitrosodiisopropylamine) are small N-Nitrosamines with similar structures, differing in that the former compound has an additional α-hydrogen atom. In this study, NEIPA and NEIPA doses, 25-100 mg/kg, were administered orally to C57BL/6 J mice for seven consecutive days, and their mutation and DNA damage effects were compared. Compared with NDIPA, the mutagenicity and DNA damage potencies of NEIPA (which contains one more α-hydrogen) were much greater. These differences may be related to their distinct metabolic pathways and target organs. This case study confirms the role of α-hydroxyl modification in the mutagenicity of nitrosamines, with oxidation at the α-hydrogen being a crucial step in the formation of mutagens from N-Nitrosamines, and can inform mutagenicity risk assessment and the formulation of regulatory standards for N-nitrosamine impurities.
Collapse
Affiliation(s)
- Qian Ye
- China Pharmaceutical University, Nanjing 211198, PR China
| | - Xingchao Geng
- National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, Beijing 100176, PR China
| | - Hua Jiang
- National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, Beijing 100176, PR China
| | - Chao Qin
- National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, Beijing 100176, PR China
| | - Hui Wu
- China Pharmaceutical University, Nanjing 211198, PR China; National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, Beijing 100176, PR China
| | - Sanlong Wang
- National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, Beijing 100176, PR China
| | - Hairuo Wen
- National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, Beijing 100176, PR China.
| |
Collapse
|
2
|
Dobrovolsky VN, Atiq OT, Heflich RH, Maisha M, McKinzie PB, Pearce MG, Robison TW. Erythrocyte PIG-A mutant frequencies in cancer patients receiving cisplatin. Cancer Med 2024; 13:e6895. [PMID: 38214136 PMCID: PMC10905239 DOI: 10.1002/cam4.6895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 12/04/2023] [Accepted: 12/19/2023] [Indexed: 01/13/2024] Open
Abstract
BACKGROUND Cisplatin is a primary chemotherapy choice for various solid tumors. DNA damage caused by cisplatin results in apoptosis of tumor cells. Cisplatin-induced DNA damage, however, may also result in mutations in normal cells and the initiation of secondary malignancies. In the current study, we have used the erythrocyte PIG-A assay to evaluate mutagenesis in non-tumor hematopoietic tissue of cancer patients receiving cisplatin chemotherapy. METHODS Twenty-one head and neck cancer patients undergoing treatment with cisplatin were monitored for the presence of PIG-A mutant total erythrocytes and the young erythrocytes, reticulocytes (RETs), in peripheral blood for up to five and a half months from the initiation of the anti-neoplastic chemotherapy. RESULTS PIG-A mutant frequency (MF) in RETs increased at least two-fold in 15 patients at some point of the monitoring, while the frequency of total mutant RBCs increased at least two-fold in 6 patients. A general trend for an increase in the frequency of mutant RETs and total mutant RBCs was observed in 19 and 18 patients, respectively. Only in one patient did both RET and total RBC PIG-A MFs did not increase at any time-point over the monitoring period. CONCLUSION Cisplatin chemotherapy induces moderate increases in the frequency of PIG-A mutant erythrocytes in head and neck cancer patients. Mutagenicity measured with the flow cytometric PIG-A assay may serve as a tool for predicting adverse outcomes of genotoxic antineoplastic therapy.
Collapse
Affiliation(s)
- Vasily N. Dobrovolsky
- Division of Genetic and Molecular ToxicologyNational Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)JeffersonArkansasUSA
| | - Omar T. Atiq
- University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer InstituteLittle RockArkansasUSA
| | - Robert H. Heflich
- Division of Genetic and Molecular ToxicologyNational Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)JeffersonArkansasUSA
| | - Mackean Maisha
- Office of Scientific Coordination, NCTR, FDAJeffersonArkansasUSA
| | - Page B. McKinzie
- Division of Genetic and Molecular ToxicologyNational Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)JeffersonArkansasUSA
| | - Mason G. Pearce
- Division of Genetic and Molecular ToxicologyNational Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)JeffersonArkansasUSA
| | - Timothy W. Robison
- Office of New Drugs, OII, DPTII, Center for Drug Evaluation and Research (CDER), US FDASilver SpringMarylandUSA
| |
Collapse
|
3
|
Smith-Roe SL, Hobbs CA, Hull V, Todd Auman J, Recio L, Streicker MA, Rivas MV, Pratt GA, Lo FY, Higgins JE, Schmidt EK, Williams LN, Nachmanson D, Valentine Iii CC, Salk JJ, Witt KL. Adopting duplex sequencing technology for genetic toxicity testing: A proof-of-concept mutagenesis experiment with N-ethyl-N-nitrosourea (ENU)-exposed rats. MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2023; 891:503669. [PMID: 37770135 PMCID: PMC10539650 DOI: 10.1016/j.mrgentox.2023.503669] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Revised: 07/31/2023] [Accepted: 08/01/2023] [Indexed: 09/30/2023]
Abstract
Duplex sequencing (DS) is an error-corrected next-generation sequencing method in which molecular barcodes informatically link PCR-copies back to their source DNA strands, enabling computational removal of errors in consensus sequences. The resulting background of less than one artifactual mutation per 107 nucleotides allows for direct detection of somatic mutations. TwinStrand Biosciences, Inc. has developed a DS-based mutagenesis assay to sample the rat genome, which can be applied to genetic toxicity testing. To evaluate this assay for early detection of mutagenesis, a time-course study was conducted using male Hsd:Sprague Dawley SD rats (3 per group) administered a single dose of 40 mg/kg N-ethyl-N-nitrosourea (ENU) via gavage, with mutation frequency (MF) and spectrum analyzed in stomach, bone marrow, blood, and liver tissues at 3 h, 24 h, 7 d, and 28 d post-exposure. Significant increases in MF were observed in ENU-exposed rats as early as 24 h for stomach (site of contact) and bone marrow (a highly proliferative tissue) and at 7 d for liver and blood. The canonical, mutational signature of ENU was established by 7 d post-exposure in all four tissues. Interlaboratory analysis of a subset of samples from different tissues and time points demonstrated remarkable reproducibility for both MF and spectrum. These results demonstrate that MF and spectrum can be evaluated successfully by directly sequencing targeted regions of DNA obtained from various tissues, a considerable advancement compared to currently used in vivo gene mutation assays.
Collapse
Affiliation(s)
| | - Cheryl A Hobbs
- Integrated Laboratory Systems, LLC (An Inotiv Company), Research Triangle Park, NC, USA
| | - Victoria Hull
- Integrated Laboratory Systems, LLC (An Inotiv Company), Research Triangle Park, NC, USA
| | - J Todd Auman
- Integrated Laboratory Systems, LLC (An Inotiv Company), Research Triangle Park, NC, USA
| | - Leslie Recio
- Integrated Laboratory Systems, LLC (An Inotiv Company), Research Triangle Park, NC, USA
| | - Michael A Streicker
- Integrated Laboratory Systems, LLC (An Inotiv Company), Research Triangle Park, NC, USA
| | - Miriam V Rivas
- Integrated Laboratory Systems, LLC (An Inotiv Company), Research Triangle Park, NC, USA
| | | | - Fang Yin Lo
- TwinStrand Biosciences, Inc., Seattle, WA, USA
| | | | | | | | | | | | | | - Kristine L Witt
- Division of Translational Toxicology, NIEHS, Research Triangle Park, NC, USA
| |
Collapse
|
4
|
Smith-Roe SL, Hobbs CA, Hull V, Auman JT, Recio L, Streicker MA, Rivas MV, Pratt GA, Lo FY, Higgins JE, Schmidt EK, Williams LN, Nachmanson D, Valentine CC, Salk JJ, Witt KL. Adopting Duplex Sequencing™ Technology for Genetic Toxicity Testing: A Proof-of-Concept Mutagenesis Experiment with N-Ethyl-N-Nitrosourea (ENU)-Exposed Rats. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.05.08.539833. [PMID: 37214853 PMCID: PMC10197591 DOI: 10.1101/2023.05.08.539833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Duplex sequencing (DuplexSeq) is an error-corrected next-generation sequencing (ecNGS) method in which molecular barcodes informatically link PCR-copies back to their source DNA strands, enabling computational removal of errors by comparing grouped strand sequencing reads. The resulting background of less than one artifactual mutation per 10 7 nucleotides allows for direct detection of somatic mutations. TwinStrand Biosciences, Inc. has developed a DuplexSeq-based mutagenesis assay to sample the rat genome, which can be applied to genetic toxicity testing. To evaluate this assay for early detection of mutagenesis, a time-course study was conducted using male Hsd:Sprague Dawley SD rats (3 per group) administered a single dose of 40 mg/kg N-ethyl-N-nitrosourea (ENU) via gavage, with mutation frequency (MF) and spectrum analyzed in stomach, bone marrow, blood, and liver tissues at 3 h, 24 h, 7 d, and 28 d post-exposure. Significant increases in MF were observed in ENU-exposed rats as early as 24 h for stomach (site of contact) and bone marrow (a highly proliferative tissue) and at 7 d for liver and blood. The canonical, mutational signature of ENU was established by 7 d post-exposure in all four tissues. Interlaboratory analysis of a subset of samples from different tissues and time points demonstrated remarkable reproducibility for both MF and spectrum. These results demonstrate that MF and spectrum can be evaluated successfully by directly sequencing targeted regions of DNA obtained from various tissues, a considerable advancement compared to currently used in vivo gene mutation assays. HIGHLIGHTS DuplexSeq is an ultra-accurate NGS technology that directly quantifies mutationsENU-dependent mutagenesis was detected 24 h post-exposure in proliferative tissuesMultiple tissues exhibited the canonical ENU mutation spectrum 7 d after exposureResults obtained with DuplexSeq were highly concordant between laboratoriesThe Rat-50 Mutagenesis Assay is promising for applications in genetic toxicology.
Collapse
Affiliation(s)
| | - Cheryl A. Hobbs
- Integrated Laboratory Systems, LLC (an Inotiv company), Research Triangle Park, NC
| | - Victoria Hull
- Integrated Laboratory Systems, LLC (an Inotiv company), Research Triangle Park, NC
| | - J. Todd Auman
- Integrated Laboratory Systems, LLC (an Inotiv company), Research Triangle Park, NC
| | - Leslie Recio
- Integrated Laboratory Systems, LLC (an Inotiv company), Research Triangle Park, NC
| | - Michael A. Streicker
- Integrated Laboratory Systems, LLC (an Inotiv company), Research Triangle Park, NC
| | - Miriam V. Rivas
- Integrated Laboratory Systems, LLC (an Inotiv company), Research Triangle Park, NC
| | | | | | | | | | | | | | | | | | - Kristine L. Witt
- Division of Translational Toxicology, NIEHS, Research Triangle Park, NC
| |
Collapse
|
5
|
Landsiedel R, Honarvar N, Seiffert SB, Oesch B, Oesch F. Genotoxicity testing of nanomaterials. WIRES NANOMEDICINE AND NANOBIOTECHNOLOGY 2022; 14:e1833. [DOI: 10.1002/wnan.1833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 06/02/2022] [Accepted: 06/06/2022] [Indexed: 11/24/2022]
Affiliation(s)
- Robert Landsiedel
- Experimental Toxicology and Ecology BASF SE Ludwigshafen am Rhein Germany
- Pharmacy, Pharmacology and Toxicology Free University of Berlin Berlin Germany
| | - Naveed Honarvar
- Experimental Toxicology and Ecology BASF SE Ludwigshafen am Rhein Germany
| | | | - Barbara Oesch
- Oesch‐Tox Toxicological Consulting and Expert Opinions, GmbH & Co KG Ingelheim Germany
| | - Franz Oesch
- Oesch‐Tox Toxicological Consulting and Expert Opinions, GmbH & Co KG Ingelheim Germany
- Institute of Toxicology Johannes Gutenberg University Mainz Germany
| |
Collapse
|
6
|
Waters MD, Warren S, Hughes C, Lewis P, Zhang F. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2022; 63:37-63. [PMID: 35023215 DOI: 10.1002/em.22471] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 12/28/2021] [Accepted: 01/08/2022] [Indexed: 06/14/2023]
Abstract
This review considers antiviral nucleoside analog drugs, including ribavirin, favipiravir, and molnupiravir, which induce genome error catastrophe in SARS-CoV or SARS-CoV-2 via lethal mutagenesis as a mode of action. In vitro data indicate that molnupiravir may be 100 times more potent as an antiviral agent than ribavirin or favipiravir. Molnupiravir has recently demonstrated efficacy in a phase 3 clinical trial. Because of its anticipated global use, its relative potency, and the reported in vitro "host" cell mutagenicity of its active principle, β-d-N4-hydroxycytidine, we have reviewed the development of molnupiravir and its genotoxicity safety evaluation, as well as the genotoxicity profiles of three congeners, that is, ribavirin, favipiravir, and 5-(2-chloroethyl)-2'-deoxyuridine. We consider the potential genetic risks of molnupiravir on the basis of all available information and focus on the need for additional human genotoxicity data and follow-up in patients treated with molnupiravir and similar drugs. Such human data are especially relevant for antiviral NAs that have the potential of permanently modifying the genomes of treated patients and/or causing human teratogenicity or embryotoxicity. We conclude that the results of preclinical genotoxicity studies and phase 1 human clinical safety, tolerability, and pharmacokinetics are critical components of drug safety assessments and sentinels of unanticipated adverse health effects. We provide our rationale for performing more thorough genotoxicity testing prior to and within phase 1 clinical trials, including human PIG-A and error corrected next generation sequencing (duplex sequencing) studies in DNA and mitochondrial DNA of patients treated with antiviral NAs that induce genome error catastrophe via lethal mutagenesis.
Collapse
Affiliation(s)
- Michael D Waters
- Michael Waters Consulting USA, Hillsborough, North Carolina, USA
| | | | - Claude Hughes
- Duke University Medical Center, Durham, North Carolina, USA
| | | | - Fengyu Zhang
- Global Clinical and Translational Research Institute, Bethesda, Maryland, USA
| |
Collapse
|
7
|
Molecular characterization of hypoxanthine guanine phosphoribosyltransferase mutant T cells in human blood: The concept of surrogate selection for immunologically relevant cells. MUTATION RESEARCH. REVIEWS IN MUTATION RESEARCH 2022; 789:108414. [PMID: 35690417 PMCID: PMC9188651 DOI: 10.1016/j.mrrev.2022.108414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 03/01/2022] [Accepted: 03/08/2022] [Indexed: 11/23/2022]
Abstract
Somatic cell gene mutations arise in vivo due to replication errors during DNA synthesis occurring spontaneously during normal DNA synthesis or as a result of replication on a DNA template damaged by endogenous or exogenous mutagens. In principle, changes in the frequencies of mutant cells in vivo in humans reflect changes in exposures to exogenous or endogenous DNA damaging insults, other factors being equal. It is becoming increasingly evident however, that somatic mutations in humans have a far greater range of interpretations. For example, mutations in lymphocytes provide invaluable probes for in vivo cellular and molecular processes, providing identification of clonal amplifications of these cells in autoimmune and infectious diseases, transplantation recipients, paroxysmal nocturnal hemoglobinuria (PNH), and cancer. The assay for mutations of the X-chromosomal hypoxanthine guanine phosphoribosyltransferase (HPRT) gene has gained popular acceptance for this purpose since viable mutant cells can be recovered for molecular and other analyses. Although the major application of the HPRT T cell assay remains human population monitoring, the enrichment of activated T cells in the mutant fraction in individuals with ongoing immunological processes has demonstrated the utility of surrogate selection, a method that uses somatic mutation as a surrogate marker for the in vivo T cell proliferation that underlies immunological processes to investigate clinical disorders with immunological features. Studies encompassing a wide range of clinical conditions are reviewed. Despite the historical importance of the HPRT mutation system in validating surrogate selection, there are now additional mutational and other methods for identifying immunologically active T cells. These methods are reviewed and provide insights for strategies to extend surrogate selection in future studies.
Collapse
|
8
|
Elhajouji A, Hove TT, O'Connell O, Martus H, Dertinger SD. Pig-a gene mutation assay study design: critical assessment of 3- versus 28-day repeat-dose treatment schedules. Mutagenesis 2021; 35:349-358. [PMID: 32608486 DOI: 10.1093/mutage/geaa014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Accepted: 05/27/2020] [Indexed: 11/12/2022] Open
Abstract
The in vivo Pig-a assay is being used in safety studies to evaluate the potential of chemicals to induce somatic cell gene mutations. Ongoing work is aimed at developing an Organisation for Economic Cooperation and Development (OECD) test guideline to support routine use for regulatory purposes (OECD project number 4.93). Among the details that will need to be articulated in an eventual guideline are recommended treatment and harvest schedules. With this in mind, experiments reported herein were performed with Wistar Han rats exposed to aristolochic acid I (AA), 1,3-propane sultone, chlorambucil, thiotepa or melphalan using each of two commonly used treatment schedules: 3 or 28 consecutive days. In the case of the 3-day studies, blood was collected for Pig-a analysis on days 15 or 16 and 29 or 30. For the 28-day studies blood was collected on day 29 or 30. The effect of treatment on mutant reticulocytes and mutant erythrocytes was evaluated with parametric pair-wise tests. While each of the five mutagens increased mutant phenotype cell frequencies irrespective of study design, statistical significance was consistently achieved at lower dose levels when the 28-day format was used (e.g. 2.75 vs 20 mg/kg/bw for AA). To more thoroughly investigate the dose-response relationships, benchmark dose (BMD) analyses were performed with PROAST software. These results corroborate the pair-wise testing results in that lower BMD values were obtained with the 28-day design. Finally, mutagenic potency, as measured by BMD analyses, most consistently correlated with the mutagens' tumorigenic dose 50 values when the lengthier treatment schedule was used. Collectively, these results suggest that both 3- and 28-day treatment schedules have merit in hazard identification-type studies. That being said, for the purpose of regulatory safety assessments, there are clear advantages to study designs that utilise protracted exposures.
Collapse
Affiliation(s)
- Azeddine Elhajouji
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, WKL-135.2.25, Basel, Switzerland
| | - Tamsanqa Tafara Hove
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, WKL-135.2.25, Basel, Switzerland
| | - Oliver O'Connell
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, WKL-135.2.25, Basel, Switzerland
| | - Hansjoerg Martus
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, WKL-135.2.25, Basel, Switzerland
| | | |
Collapse
|
9
|
Chikura S, Kimoto T, Itoh S, Sanada H, Muto S, Horibata K. Standard protocol for the PIGRET assay, a high-throughput reticulocyte Pig-a assay with an immunomagnetic separation, used in the interlaboratory trial organized by the Mammalian Mutagenicity Study Group of the Japanese Environmental Mutagen and Genome Society. Genes Environ 2021; 43:10. [PMID: 33743813 PMCID: PMC7981892 DOI: 10.1186/s41021-021-00181-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Accepted: 02/23/2021] [Indexed: 12/11/2022] Open
Abstract
The PIGRET assay is one of the Pig-a assays targeting reticulocytes (RETs), an in vivo genotoxicity evaluation method using flow cytometry with endogenous reporter glycosylphosphatidylinositol anchor protein. The PIGRET assay with RETs selectively enriched with anti-CD71 antibodies has several desirable features: high-throughput assay system, low background frequency of mutant cells, and early detection of mutation. To verify the potential and usefulness of the PIGRET assay for short-term testing, an interlaboratory trial involving 16 laboratories organized by the Mammalian Mutagenicity Study Group of the Japanese Environmental Mutagen and Genome Society was conducted. The collaborating laboratories assessed the mutagenicities of a total of 24 chemicals in rats using a single-treatment design and standard protocols for conducting the Pig-a assay on the total red blood cell assay and the PIGRET assay. Here the standard protocol for the PIGRET assay was described in detail.
Collapse
Affiliation(s)
- Satsuki Chikura
- Toxicology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited, 4-3-2 Asahigaoka, Hino-shi, Tokyo, 191-8512, Japan
| | - Takafumi Kimoto
- Toxicology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited, 4-3-2 Asahigaoka, Hino-shi, Tokyo, 191-8512, Japan.
| | - Satoru Itoh
- Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd., 1-16-13, Kitakasai, Edogawa-ku, Tokyo, 134-8630, Japan
| | - Hisakazu Sanada
- Development ADMET Department, Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, 412-8513, Japan
| | - Shigeharu Muto
- Safety Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa, 251-8555, Japan
| | - Katsuyoshi Horibata
- Division of Genetics and Mutagenesis, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-9501, Japan.
| |
Collapse
|
10
|
Dertinger SD, Bhalli JA, Roberts DJ, Stankowski LF, Gollapudi BB, Lovell DP, Recio L, Kimoto T, Miura D, Heflich RH. Recommendations for conducting the rodent erythrocyte Pig-a assay: A report from the HESI GTTC Pig-a Workgroup. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2021; 62:227-237. [PMID: 33608913 PMCID: PMC7986863 DOI: 10.1002/em.22427] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 02/08/2021] [Accepted: 02/17/2021] [Indexed: 05/19/2023]
Abstract
The rodent Pig-a assay is a flow cytometric, phenotype-based method used to measure in vivo somatic cell mutation. An Organization for Economic Co-operation and Development (OECD) test guideline is currently being developed to support routine use of the assay for regulatory purposes (OECD project number 4.93). This article provides advice on best practices for designing and conducting rodent Pig-a studies in support of evaluating test substance safety, with a focus on the rat model. Various aspects of assay conduct, including laboratory proficiency, minimum number of animals per dose group, preferred treatment and blood sampling schedule, and statistical analysis are described.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Leslie Recio
- Integrated Laboratory SystemsResearch Triangle ParkNorth CarolinaUSA
| | | | | | | |
Collapse
|
11
|
Ware RE, Dertinger SD. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. Br J Haematol 2021; 194:252-266. [PMID: 33570176 DOI: 10.1111/bjh.17323] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Accepted: 12/21/2020] [Indexed: 12/21/2022]
Abstract
Hydroxyurea (hydroxycarbamide) is approved for treating both children and adults with sickle cell anaemia (SCA). Fetal haemoglobin (HbF) induction is the primary treatment response, along with improved anaemia, reduced haemolysis, myelosuppression and decreased endothelial inflammation. Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival. Despite these recognised benefits, long-standing concerns regarding the risks of mutagenic and potentially carcinogenic drug exposure have hampered efforts for broad hydroxyurea use in SCA, although these are based largely on outdated experimental models and treatment experiences with myeloproliferative neoplasms. Consequently, many patients with SCA are not receiving this highly effective disease-modifying therapy. In this review, we describe the concept of genotoxicity and its laboratory measurements, summarise hydroxyurea-associated data from both preclinical and clinical studies, and discuss carcinogenic potential. The genotoxicity results clearly demonstrate that hydroxyurea does not directly bind DNA and is not mutagenic. Rather, its genotoxic effects are limited to indirect clastogenicity occurring in select cell types, and only when high dose and time thresholds are exceeded. This absence of mutagenic activity is consistent with the observed lack of any compelling carcinogenic potential. Since hydroxyurea therapy for SCA carries minimal carcinogenic risks, the current drug labelling should be modified accordingly, and prescribing practices should be broadened to allow better access and increased utilisation of this highly effective drug.
Collapse
Affiliation(s)
- Russell E Ware
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.,Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.,Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | | |
Collapse
|
12
|
Torous DK, Avlasevich SL, Khattab MG, Baig A, Saubermann LJ, Chen Y, Bemis JC, Lovell DP, Walker VE, MacGregor JT, Dertinger SD. Human blood PIG-A mutation and micronucleated reticulocyte flow cytometric assays: Method optimization and evaluation of intra- and inter-subject variation. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2020; 61:807-819. [PMID: 32572998 PMCID: PMC8582004 DOI: 10.1002/em.22393] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 06/17/2020] [Accepted: 06/18/2020] [Indexed: 05/05/2023]
Abstract
We previously described flow cytometry-based methods for scoring the incidence of micronucleated reticulocytes (MN-RET) and PIG-A mutant phenotype reticulocytes (MUT RET) in rodent and human blood samples. The current report describes important methodological improvements for human blood analyses, including immunomagnetic enrichment of CD71-positive reticulocytes prior to MN-RET scoring, and procedures for storing frozen blood for later PIG-A analysis. Technical replicate variability in MN-RET and MUT RET frequencies based on blood specimens from 14 subjects, intra-subject variability based on serial blood draws from 6 subjects, and inter-subject variation based on up to 344 subjects age 0 to 73 years were quantified. Inter-subject variation explained most of the variability observed for both endpoints (≥77%), with much lower intra-subject and technical replicate variability. The relatively large degree of inter-subject variation is apparent from mean and standard deviation values for MN-RET (0.15 ± 0.10%) and MUT RET (4.7 ± 5.0 per million, after omission of two extreme outliers). The influences of age and sex on inter-subject variation were investigated, and neither factor affected MN-RET whereas both influenced MUT RET frequency. The lowest MUT RET values were observed for subjects <11 years old, and males had moderately higher frequencies than females. These results indicate that MN-RET and MUT RET are automation-compatible biomarkers of genotoxicity that bridge species of toxicological interest to include human populations. These data will be useful for appropriately designing future human studies that include these biomarkers of genotoxicity, and highlight the need for additional work aimed at identifying the sources of inter-individual variability reported herein.
Collapse
Affiliation(s)
| | | | - Mona G. Khattab
- Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas
| | - Ayesha Baig
- Department of Pediatrics, University of Rochester Medical Center, Rochester, New York
| | | | - Yuhchyau Chen
- Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York
| | | | | | - Vernon E. Walker
- Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont
| | | | | |
Collapse
|
13
|
Dertinger SD, Avlasevich SL, Torous DK, Bemis JC, Hove TT, O'Connell O, Martus H, Elhajouji A. Intra- and inter-laboratory reproducibility of the rat blood Pig-a gene mutation assay. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2020; 61:500-507. [PMID: 32187725 DOI: 10.1002/em.22367] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 02/24/2020] [Accepted: 03/13/2020] [Indexed: 06/10/2023]
Abstract
The in vivo Pig-a assay is being used in safety studies to evaluate the potential of chemicals to induce somatic cell gene mutations. Ongoing work is aimed at developing an Organization for Economic Cooperation and Development (OECD) test guideline to support routine use for regulatory purposes (OECD project number 4.93). Among the requirements for OECD approval are demonstrations of assay reliability, including reproducibility within and among laboratories. Experiments reported herein address the reproducibility of the rat blood Pig-a assay using the reference mutagens chlorambucil and melphalan. These agents were evaluated for their ability to induce Pig-a mutant erythrocytes in three separate studies conducted across two laboratories. Each of the studies utilized a common treatment schedule: 28 consecutive days of exposure via oral gavage. Whereas one laboratory studied Crl:CD(SD) rats, the other laboratory used Wistar Han rats. One or two days after cessation of treatment blood samples were collected for mutant reticulocyte and mutant erythrocyte measurements that were accomplished with the same analytical technique whereby samples were depleted of wildtype erythrocytes via immunomagnetic separation followed by flow cytometric enumeration of mutant phenotype cells (MutaFlow®). Dunnett's test results showed similar qualitative outcomes within and between laboratories, that is, each chemical and each study demonstrated statistically significant, dose-related increases in mutant reticulocyte and erythrocyte frequencies. Benchmark dose analysis (PROAST software) provided a means to quantitatively analyze the results, and the relatively tight, overlapping benchmark dose confidence intervals observed for each of the two chemicals indicate that within and between laboratory reproducibility of the Pig-a assay are high, adding further support for the development of an OECD test guideline.
Collapse
Affiliation(s)
| | | | | | | | - Tamsanqa Tafara Hove
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Oliver O'Connell
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Hansjoerg Martus
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Azeddine Elhajouji
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| |
Collapse
|
14
|
Abstract
In addition to chromosomal damage, assessment of gene mutation is an important part of genotoxicity testing employed during preclinical safety testing. The Pig-a gene mutation assay is based on the loss of function of the Pig-a gene, which results in a lack of cell surface expression of specific proteins that are targeted to the surface by GPI anchors. This cell surface phenotype is readily assessed by flow cytometric analysis of red blood cells. This chapter describes a procedure for the collection, processing, and analysis of peripheral blood samples using materials supplied in MutaFlow® kits and a common benchtop flow cytometer.
Collapse
|
15
|
Bhalli JA, Neft R, Noteboom J, Tebbe CC, Chan M, Kuhn K, Pearce G, Jordan L, Beevers C. Caffeic Acid Genotoxicity: Correlation of the Pig-a Assay with Regulatory Genetic Toxicology In Vivo Endpoints. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:837-844. [PMID: 31490579 DOI: 10.1002/em.22333] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 08/26/2019] [Accepted: 08/30/2019] [Indexed: 05/14/2023]
Abstract
Caffeic acid is found in variety of fruits and vegetables. It is considered as possible human carcinogen (Group 2B). It is negative in Ames and mouse micronucleus (MN), but positive in mouse lymphoma and chromosomal aberration assays. The objective of this study was to evaluate the in vivo genotoxicity of caffeic acid using three different endpoints: in vivo MN, Pig-a, and comet assay. Two sets of six rats per group were administered vehicle (0.5% hydroxypropyl methylcellulose), 500, 1,000, or 2,000 mg/kg/day of caffeic acid for three consecutive days via oral gavage. One set of animals was used for the Pig-a and MN assay and the other set was used for the comet assay. N-Ethyl N-Nitrosourea was used as positive control for the Pig-a and MN assay, and ethyl methanesulfonate for the comet assay. From one set of animals, peripheral blood was collected on Days -1, 14, and 30 for the Pig-a assay and on Day 4 for the MN assay. The other set of animals was euthanized 3 hr after the last dose; liver and blood were collected for the comet assay. A statistically significant increase in the MN frequency was observed at 2,000 mg/kg/day. No increase in the red blood cells (RBCCD59- ) or reticulocytes (RETCD59- ) Pig-a mutant frequencies was observed on Days 14 or 30. No increase in DNA strand breaks was observed in the peripheral blood or liver in the comet assay. Environ. Mol. Mutagen. 2019. © 2019 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
| | - Robin Neft
- Covance Laboratories Inc., Greenfield, Indiana
| | | | | | | | - Kylie Kuhn
- Covance Laboratories Inc., Greenfield, Indiana
| | - Gareth Pearce
- Covance Laboratories Limited, Harrogate, HG3 1PY, United Kingdom
| | - Liam Jordan
- Covance Laboratories Limited, Harrogate, HG3 1PY, United Kingdom
| | - Carol Beevers
- Covance Laboratories Limited, Harrogate, HG3 1PY, United Kingdom
| |
Collapse
|
16
|
Tong W, Zhou C, Huang P, Ma J, Chang Y. Integration of micronucleus, comet, and Pig-a gene mutation endpoints into rat 15-day repeat-treatment studies: Proof-of-principle with Auramine O. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2019; 846:403072. [DOI: 10.1016/j.mrgentox.2019.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 06/30/2019] [Accepted: 07/02/2019] [Indexed: 01/05/2023]
|
17
|
Dertinger SD, Avlasevich SL, Torous DK, Singh P, Khanal S, Kirby C, Drake A, MacGregor JT, Bemis JC. 3Rs friendly study designs facilitate rat liver and blood micronucleus assays and Pig-a gene mutation assessments: Proof-of-concept with 13 reference chemicals. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:704-739. [PMID: 31294869 PMCID: PMC8600442 DOI: 10.1002/em.22312] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 05/31/2019] [Accepted: 06/11/2019] [Indexed: 05/16/2023]
Abstract
Regulatory guidance documents stress the value of assessing the most appropriate endpoints in multiple tissues when evaluating the in vivo genotoxic potential of chemicals. However, conducting several independent studies to evaluate multiple endpoints and/or tissue compartments is resource intensive. Furthermore, when dependent on visual detection, conventional approaches for scoring genotoxicity endpoints can be slow, tedious, and less objective than the ideal. To address these issues with current practices we attempted to (1) devise resource sparing treatment and harvest schedules that are compatible with liver and blood micronucleus endpoints, as well as the Pig-a gene mutation assay, and (2) utilize flow cytometry-based methods to score each of these genotoxicity biomarkers. Proof-of-principle experiments were performed with 4-week-old male and female Crl:CD(SD) rats exposed to aristolochic acids I/II, benzo[a]pyrene, cisplatin, cyclophosphamide, diethylnitrosamine, 1,2-dimethylhydrazine, dimethylnitrosamine, 2,6-dinitrotoluene, hydroxyurea, melphalan, temozolomide, quinoline, or vinblastine. These 13 chemicals were each tested in two treatment regimens: one 3-day exposure cycle, and three 3-day exposure cycles. Each exposure, blood collection, and liver harvest was accomplished during a standard Monday-Friday workweek. Key findings are that even these well-studied, relatively potent genotoxicants were not active in both tissues and all assays (indeed only cisplatin was clearly positive in all three assays); and whereas the sensitivity of the Pig-a assay clearly benefitted from three versus one treatment cycle, micronucleus assays yielded qualitatively similar results across both study designs. Collectively, these results suggest it is possible to significantly reduce animal and other resource requirements while improving assessments of in vivo genotoxicity potential by simultaneously evaluating three endpoints and two important tissue compartments using fit-for-purpose study designs in conjunction with flow cytometric scoring approaches. Environ. Mol. Mutagen., 60:704-739, 2019. © 2019 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Stephen D. Dertinger
- Litron Laboratories, Rochester, New York
- Correspondence to: Stephen D. Dertinger and Jeffrey C. Bemis, Litron Laboratories, 3500 Winton Place, Rochester, NY 14623, and
| | | | | | | | | | | | | | | | - Jeffrey C. Bemis
- Litron Laboratories, Rochester, New York
- Correspondence to: Stephen D. Dertinger and Jeffrey C. Bemis, Litron Laboratories, 3500 Winton Place, Rochester, NY 14623, and
| |
Collapse
|
18
|
Shemansky JM, McDaniel LP, Klimas C, Dertinger SD, Dobrovolsky VN, Kimoto T, Horibata K, Polli JE, Heflich RH. Pig-a gene mutation database. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:759-762. [PMID: 31090953 DOI: 10.1002/em.22298] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Accepted: 05/10/2019] [Indexed: 06/09/2023]
Abstract
Mutations in the X-linked phosphatidylinositol glycan, class A gene (Pig-a) lead to loss of glycosylphosphatidylinositol (GPI) anchors and GPI-anchored proteins from the surface of erythrocytes and other mammalian cells. The Pig-a gene mutation assay quantifies in vivo gene mutation by immunofluorescent labeling and flow cytometry to detect the loss of GPI-anchored proteins on peripheral blood erythrocytes. As part of the regulatory acceptance of the assay, a public database has been created that provides detailed information on Pig-a gene mutation assays conducted in rats and mice. A searchable version of the database is available through a website designed and hosted by the University of Maryland School of Pharmacy. Currently, the database contains only mouse and rat data, but it is anticipated that it will expand to include data from other species, including humans. A major purpose in developing the database was to aid in the preparation of a Retrospective Performance Analysis and Detailed Review Paper required for Organisation for Economic Co-operation and Development Test Guideline acceptance. We anticipate, however, that it also will be useful for accessing and comparing Pig-a data to data from other assays and for conducting quantitative assessments of Pig-a gene mutation responses. Environ. Mol. Mutagen., 60:759-762, 2019. © 2019 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Jennifer M Shemansky
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| | - Lea Patrice McDaniel
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| | | | | | - Vasily N Dobrovolsky
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| | - Takafumi Kimoto
- Teijin Institute for Bio-medical Research, Teijin Pharma Limited, Tokyo, Japan
| | | | - James E Polli
- University of Maryland School of Pharmacy, Baltimore, Maryland
| | - Robert H Heflich
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| |
Collapse
|
19
|
Dobo KL, Coffing S, Gunther WC, Homiski M. 2-Hydroxypyridine N-Oxide is not genotoxic in vivo. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:588-593. [PMID: 31001845 DOI: 10.1002/em.22294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 04/12/2019] [Accepted: 04/15/2019] [Indexed: 06/09/2023]
Abstract
2-Hydroxypyridine N-oxide (HOPO) is an important coupling reagent used in pharmaceutical synthesis. Our laboratory previously reported HOPO as equivocal in the Ames assay following extensive testing of multiple lots of material. Given the lack of reproducibility between lots of material and the weak increase in revertants observed, it was concluded that it would be highly unlikely that HOPO would pose a mutagenic risk in vivo. The purpose of the current investigation was to assess experimentally in rats the mutagenic (Pig-a mutation induction) and more broadly genotoxic (micronucleus and comet induction) potential of HOPO. Rats were administered HOPO (0, 50, 150, 300, and 500 mg/kg/day) by oral gavage for 28 days. At the end of study, the following parameters were assessed: frequency of Pig-a mutant red blood cells and reticulocytes, frequency of peripheral blood micronuclei, and the incidence of comet formation in liver. Toxicokinetic data collected on study Days 1 and 28 demonstrated systemic exposure to HOPO. Although there were no overt clinical signs, animals treated with HOPO showed a dose-related decrease in body weight gain. There were no increases observed in any of the genotoxicity endpoints assessed. The results from this study further support the conclusion that in the context of pharmaceutical synthesis, HOPO should not be considered a mutagenic impurity but rather controlled as a normal process-related impurity. Environ. Mol. Mutagen. 2019. © 2019 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Krista L Dobo
- Pfizer Worldwide Research and Development, Drug Safety, Genetic Toxicology Center of Emphasis, Groton, Connecticut
| | - Stephanie Coffing
- Pfizer Worldwide Research and Development, Drug Safety, Genetic Toxicology Center of Emphasis, Groton, Connecticut
| | - William C Gunther
- Pfizer Worldwide Research and Development, Drug Safety, Genetic Toxicology Center of Emphasis, Groton, Connecticut
| | - Michael Homiski
- Pfizer Worldwide Research and Development, Drug Safety, Genetic Toxicology Center of Emphasis, Groton, Connecticut
| |
Collapse
|
20
|
Kirkland D, Uno Y, Luijten M, Beevers C, van Benthem J, Burlinson B, Dertinger S, Douglas GR, Hamada S, Horibata K, Lovell DP, Manjanatha M, Martus HJ, Mei N, Morita T, Ohyama W, Williams A. In vivo genotoxicity testing strategies: Report from the 7th International workshop on genotoxicity testing (IWGT). MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2019; 847:403035. [PMID: 31699340 DOI: 10.1016/j.mrgentox.2019.03.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 03/13/2019] [Accepted: 03/23/2019] [Indexed: 12/14/2022]
Abstract
The working group reached complete or majority agreement on many issues. Results from TGR and in vivo comet assays for 91 chemicals showed they have similar ability to detect in vivo genotoxicity per se with bacterial mutagens and Ames-positive carcinogens. TGR and comet assay results were not significantly different when compared with IARC Group 1, 2 A, and unclassified carcinogens. There were significantly more comet assay positive responses for Group 2B chemicals, and for IARC classified and unclassified carcinogens combined, which may be expected since mutation is a sub-set of genotoxicity. A liver comet assay combined with the bone marrow/blood micronucleus (MNviv) test would detect in vivo genotoxins that do not exhibit tissue-specific or site-of-contact effects, and is appropriate for routine in vivo genotoxicity testing. Generally for orally administered substances, a comet assay at only one site-of-contact GI tract tissue (stomach or duodenum/jejunum) is required. In MNviv tests, evidence of target tissue exposure can be obtained in a number of different ways, as recommended by ICH S2(R1) and EFSA (Hardy et al., 2017). Except for special cases the i.p. route is inappropriate for in vivo testing; for risk evaluations more weight should be given to data from a physiologically relevant administration route. The liver MN test is sufficiently validated for the development of an OECD guideline. However, the impact of dosing animals >6 weeks of age needs to be evaluated. The GI tract MN test shows promise but needs more validation for an OECD guideline. The Pig-a assay detects systemically available mutagens and is a valuable follow-up to in vitro positive results. A new freeze-thaw protocol provides more flexibility. Mutant reticulocyte and erythrocyte frequencies should both be determined. Preliminary data are available for the Pig-a assay in male rat germ cells which require validation including germ cell DNA mutation origin.
Collapse
Affiliation(s)
- David Kirkland
- Kirkland Consulting, PO Box 79, Tadcaster, LS24 0AS, United Kingdom.
| | - Yoshifumi Uno
- Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama, 335-8505, Japan
| | - Mirjam Luijten
- National Institute for Public Health and the Environment (RIVM), Centre for Health Protection, Bilthoven, the Netherlands
| | - Carol Beevers
- Exponent International Ltd., The Lenz, Hornbeam Park, Harrogate, HG2 8RE, United Kingdom
| | - Jan van Benthem
- National Institute for Public Health and the Environment (RIVM), Centre for Health Protection, Bilthoven, the Netherlands
| | - Brian Burlinson
- Envigo, Huntingdon, Cambridgeshire, PE28 4HS, United Kingdom
| | | | - George R Douglas
- Environmental Health Science Research Bureau, Health Canada, Ottawa, K1A 0K9, Canada
| | - Shuichi Hamada
- LSI Medience Corporation, 14-1 Sunayama, Kamisu-shi, Ibaraki, 314-0255, Japan
| | - Katsuyoshi Horibata
- National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki, Kanagawa, 210-9501, Japan
| | - David P Lovell
- St George's Medical School, University of London, London, SW17 0RE, United Kingdom
| | | | | | - Nan Mei
- US FDA, National Center for Toxicological Research, Jefferson, AR, USA
| | - Takeshi Morita
- National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki, Kanagawa, 210-9501, Japan
| | - Wakako Ohyama
- Yakult Honsha Co., Ltd., 5-11, Izumi, Kunitachi-shi, Tokyo, 186-8650, Japan
| | - Andrew Williams
- Environmental Health Science Research Bureau, Health Canada, Ottawa, K1A 0K9, Canada
| |
Collapse
|
21
|
Bemis JC, Heflich RH. In vitro mammalian cell mutation assays based on the Pig-a gene: A report of the 7th International Workshop on Genotoxicity Testing (IWGT) Workgroup. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2019; 847:403028. [PMID: 31699348 DOI: 10.1016/j.mrgentox.2019.03.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Revised: 01/29/2019] [Accepted: 03/04/2019] [Indexed: 02/06/2023]
Abstract
Pig-a gene mutation assays enumerate cells with the glycosylphosphatidylinositol (GPI) anchor-deficient phenotype as a reporter of mutation in the endogenous Pig-a gene. Methods for measuring mutation in this gene are quite well established for in vivo systems. This approach to mutagenicity assessment has now been extended to in vitro mammalian cell-based systems. An expert workgroup from the 7th International Workshop on Genotoxicity Testing tasked with assessing the status of in vitro mammalian cell mutation assays has investigated the merits and limitations of in vitro Pig-a gene mutation assays. A review of the current status of these developing methodologies and the formation of consensus statements on the utility and application of these assays were performed to provide guidance for their potential use in genotoxicity hazard identification and risk assessment.
Collapse
Affiliation(s)
- J C Bemis
- Litron Laboratories, Rochester, NY, USA.
| | - R H Heflich
- US Food and Drug Administration, National Center for Toxicological Research, Jefferson, AR, USA
| |
Collapse
|
22
|
Ji Z, Settivari RS, LeBaron MJ. Pilot studies evaluating the nongenotoxic rodent carcinogens phenobarbital and clofibrate in the rat Pig-a assay. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:42-46. [PMID: 30338550 DOI: 10.1002/em.22232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 07/16/2018] [Accepted: 07/17/2018] [Indexed: 06/08/2023]
Abstract
The Pig-a assay is an emerging and promising in vivo method to determine mutagenic potential of chemicals. Since its development in 2008, remarkable progress has been made in harmonizing and characterizing the test procedures, primarily using known mutagenic chemicals. The purpose of the present study was to evaluate specificity of the Pig-a assay using two nongenotoxic and well-characterized rodent liver carcinogens, phenobarbital and clofibrate, in male F344/DuCrl rats. Daily oral administration of phenobarbital or clofibrate at established hepatotoxic doses for 28 days resulted in substantial hepatic alterations, however, did not increase the frequency of Pig-a mutation markers (RETCD59- and RBCCD59- ) compared to vehicle control or pre-exposure (Day -5) mutant frequencies. These results are consistent with the existing literature on the nonmutagenic mode of action (MoA) of phenobarbital and clofibrate liver tumors. The present study contributes to the limited, but expanding evidence on the specificity of the Pig-a assay and further for the investigations of carcinogenic MoAs, i.e., mutagenic or nonmutagenic potential of chemicals. Environ. Mol. Mutagen. 60:42-46, 2019. © 2018 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Zhiying Ji
- Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan
| | - Raja S Settivari
- Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan
| | - Matthew J LeBaron
- Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan
| |
Collapse
|
23
|
Chen G, Wen H, Mao Z, Song J, Jiang H, Wang W, Yang Y, Miao Y, Wang C, Huang Z, Wang X. Assessment of the Pig-a, micronucleus, and comet assay endpoints in rats treated by acute or repeated dosing protocols with procarbazine hydrochloride and ethyl carbamate. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:56-71. [PMID: 30240497 DOI: 10.1002/em.22227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 06/12/2018] [Accepted: 06/24/2018] [Indexed: 06/08/2023]
Abstract
The utility and sensitivity of the newly developed flow cytometric Pig-a gene mutation assay have become a great concern recently. In this study, we have examined the feasibility of integrating the Pig-a assay as well as micronucleus and Comet endpoints into acute and subchronic general toxicology studies. Male Sprague-Dawley rats were treated for 3 or 28 consecutive days by oral gavage with procarbazine hydrochloride (PCZ) or ethyl carbamate (EC) up to the maximum tolerated dose. The induction of CD59-negative reticulocytes and erythrocytes, micronucleated reticulocytes in peripheral blood, micronucleated polychromatic erythrocytes in bone marrow, and Comet responses in peripheral blood, liver, kidney, and lung were evaluated at one, two, or more timepoints. Both PCZ and EC produced positive responses at most analyzed timepoints in all tissue types, both with the 3-day and 28-day treatment regimens. Furthermore, comparison of the magnitude of the genotoxicity responses indicated that the micronucleus and Comet endpoints generally produced greater responses with the higher dose, short-term treatments in the 3-day study, while the Pig-a assay responded better to the cumulative effects of the lower dose, but repeated subchronic dosing in the 28-day study. Collectively, these results indicate that integration of several in vivo genotoxicity endpoints into a single routine toxicology study is feasible and that the Pig-a assay may be particularly suitable for integration into subchronic dose studies based on its ability to accumulate the mutations that result from repeated treatments. This characteristic may be especially important for assaying lower doses of relatively weak genotoxicants. Environ. Mol. Mutagen. 60:56-71, 2019. © 2018 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Gaofeng Chen
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
- Center of Safety Evaluation on New Drug, School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Hairuo Wen
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Zhihui Mao
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
- Center of Safety Evaluation on New Drug, School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Jie Song
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Hua Jiang
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Weifan Wang
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Ying Yang
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Yufa Miao
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Chao Wang
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Zhiying Huang
- Center of Safety Evaluation on New Drug, School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Xue Wang
- Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, People's Republic of China
| |
Collapse
|
24
|
Avlasevich SL, Torous DK, Bemis JC, Bhalli JA, Tebbe CC, Noteboom J, Thomas D, Roberts DJ, Barragato M, Schneider B, Prattico J, Richardson M, Gollapudi BB, Dertinger SD. Suitability of Long-Term Frozen Rat Blood Samples for the Interrogation of Pig-a Gene Mutation by Flow Cytometry. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:47-55. [PMID: 30264522 DOI: 10.1002/em.22249] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 08/16/2018] [Accepted: 08/24/2018] [Indexed: 06/08/2023]
Abstract
The rodent blood Pig-a assay has been undergoing international validation for use as an in vivo hematopoietic cell gene mutation assay, and given the promising results an Organization for Economic Co-operation and Development (OECD) Test Guideline is currently under development. Enthusiasm for the assay stems in part from its alignment with 3Rs principles permitting combination with other genotoxicity endpoint(s) and integration into repeat-dose toxicology studies. One logistical requirement and experimental design limitation has been that blood samples required antibody labeling and flow cytometric analysis within one week of collection. In the current report, we describe the performance of freeze-thaw reagents that enable storage and subsequent labeling and analysis of rat blood samples for at least seven months. Data generated from three laboratories are presented that demonstrate rat erythrocyte recoveries in the range of 80-90%. Despite some loss of erythrocytes, Pearson coefficients and Bland-Altman analyses based on fresh blood vs. frozen/thawed matched pairs indicate that mutant cell and reticulocyte frequencies are not significantly affected, as the measurements are highly correlated and exhibit low bias. Collectively, these data support the effectiveness and suitability of a freeze-thaw procedure that endows the assay with several new advantageous characteristics that include: flexibility in scheduling personnel/instrumentation; reliability when shipping samples from in-life facilities to analytical sites; 3Rs-friendly, as blood from positive control animals can be stored frozen to serve as analytical controls; and ability to defer a decision to generate Pig-a data until more toxicological information becomes available on a test substance. Environ. Mol. Mutagen. 60:47-55, 2019. © 2018 Wiley Periodicals, Inc.
Collapse
|
25
|
Application of the in vivo Pig-a gene mutation assay to test the potential genotoxicity of p-phenylenediamine. Food Chem Toxicol 2018; 123:424-430. [PMID: 30439388 DOI: 10.1016/j.fct.2018.10.061] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Revised: 10/17/2018] [Accepted: 10/27/2018] [Indexed: 11/21/2022]
Abstract
Currently, it remains controversial whether p-phenylenediamine (PPD) is genotoxic. In this study, we evaluated the potential genotoxicity of PPD using the newly-developed Pig-a gene mutation assay. The results of three classical genetic toxicity tests (bacterial reverse mutation assay, mammalian cell chromosomal aberration test, and mammalian erythrocyte micronucleus test) are all positive, suggesting that PPD is potentially genotoxic. In Pig-a assay, Sprague-Dawley rats are orally administered with PPD for 28 consecutive days at three doses (12.5, 25, and 50 mg/kg/day). Our result shows that PPD (25 and 50 mg/kg/day) dose-dependently increases RETCD59- value over controls on Day 8. RETCD59- keeps increasing to the maximum on Day 15 and then decreases until Day 29. PPD also dose-dependently increase RBCCD59- value on Day 15, which keeps elevating until Day 29. The time-course of RETCD59- and RBCCD59- induced by PPD are similar with that induced by N-ethyl-N-nitrosourea (ENU) treatment for 3 days. Our data suggests that PPD has potential genotoxic effects, and the Pig-a assay is sensitive to assess mutagenicity. However, further investigation of the changes of RETCD59- and RBCCD59- induced by hair dyes containing PPD should be detected by Pig-a assay in occupational exposure population to confirm the safety of PPD usage.
Collapse
|
26
|
Revollo JR, Pearce MG, Dad A, Petibone DM, Robison TW, Roberts D, Dobrovolsky VN. Analysis of mutation in the rat Pig-a assay: I) studies with bone marrow erythroid cells. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2018; 59:722-732. [PMID: 30091272 DOI: 10.1002/em.22211] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 05/08/2018] [Accepted: 05/10/2018] [Indexed: 06/08/2023]
Abstract
We have established a flow cytometry-based Pig-a assay for rat bone marrow erythroid cells (BMEs). The BME Pig-a assay uses a DNA-specific stain and two antibodies: one against the transmembrane transferrin receptor (CD71 marker) and the other against the GPI-anchored complement inhibitory protein (CD59 marker). In F344 male rats treated acutely with a total of 120 mg/kg of N-ethyl-N-nitrosourea (ENU) the frequency of CD59-deficient phenotypically mutant BMEs increased approximately 24-fold compared to the rats concurrently treated with the vehicle. Such an increase of mutant BMEs coincides with increases of CD59-deficient reticulocytes measured in rats treated with similar doses of ENU. Sequence analysis of the endogenous X-linked Pig-a gene of CD59-deficient BMEs revealed that they are Pig-a mutants. The spectrum of ENU-induced Pig-a mutations in these BMEs was consistent with the in vivo mutagenic signature of ENU: 73% of mutations occurred at A:T basepairs, with the mutated T on the nontranscribed strand of the gene. T→A transversion was the most frequent mutation followed by T→C transition; no deletion or insertion mutations were present in the spectrum. Since BMEs are precursors of peripheral red blood cells, our findings suggest that CD59-deficient erythrocytes measured in the flow cytometric erythrocyte Pig-a assay develop from BMEs containing mutations in the Pig-a gene. Thus, the erythrocyte Pig-a assay detects mutation in the Pig-a gene. Environ. Mol. Mutagen. 59:722-732, 2018. © 2018 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Javier R Revollo
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| | - Mason G Pearce
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| | - Azra Dad
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| | - Dayton M Petibone
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| | - Timothy W Robison
- Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
| | - Daniel Roberts
- Charles River Laboratories, Skokie, Illinois; Joint Graduate Program of Toxicology, Rutgers University, Piscataway, New Jersey
| | - Vasily N Dobrovolsky
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
| |
Collapse
|
27
|
Elhajouji A, Vaskova D, Downing R, Dertinger SD, Martus H. Induction ofin vivo Pig-agene mutation but not micronuclei by 5-(2-chloroethyl)-2ʹ-deoxyuridine, an antiviral pyrimidine nucleoside analogue. Mutagenesis 2018; 33:343-350. [DOI: 10.1093/mutage/gey029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Accepted: 09/10/2018] [Indexed: 11/14/2022] Open
Affiliation(s)
- Azeddine Elhajouji
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Dagmara Vaskova
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Rebecca Downing
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | | | - Hansjeorg Martus
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| |
Collapse
|
28
|
Maranghi F, Tassinari R, Narciso L, Tait S, Rocca CL, Felice GD, Butteroni C, Corinti S, Barletta B, Cordelli E, Pacchierotti F, Eleuteri P, Villani P, Hegarat LL, Fessard V, Reale O. In vivo toxicity and genotoxicity of beauvericin and enniatins. Combined approach to study in vivo toxicity and genotoxicity of mycotoxins beauvericin (BEA) and enniatin B (ENNB). ACTA ACUST UNITED AC 2018. [DOI: 10.2903/sp.efsa.2018.en-1406] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Eugenia Cordelli
- Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) Italy
| | - Francesca Pacchierotti
- Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) Italy
| | - Patrizia Eleuteri
- Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) Italy
| | - Paola Villani
- Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) Italy
| | - Ludovic Le Hegarat
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES) France
| | - Valérie Fessard
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES) France
| | - Océane Reale
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES) France
| |
Collapse
|
29
|
Khanal S, Singh P, Avlasevich SL, Torous DK, Bemis JC, Dertinger SD. Integration of liver and blood micronucleus and Pig-a gene mutation endpoints into rat 28-day repeat-treatment studies: Proof-of-principle with diethylnitrosamine. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2018; 828:30-35. [PMID: 29555062 DOI: 10.1016/j.mrgentox.2018.02.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 02/13/2018] [Accepted: 02/22/2018] [Indexed: 01/15/2023]
Abstract
Regulatory guidance documents stress the value of assessing multiple tissues and the most appropriate endpoints when evaluating chemicals for in vivo genotoxic potential. However, conducting several independent studies to consider multiple endpoints and/or tissue compartments is resource intensive. Furthermore, conventional approaches for scoring genotoxicity endpoints are slow, tedious, and less objective than what would be considered ideal. In an effort to address these issues with current practices, we attempted to i) employ flow cytometry-based methods to score liver micronuclei, blood micronuclei, and blood Pig-a gene mutation, and ii) integrate the endpoints into a common general toxicology study design-the rat 28-day repeat dose study. A proof-of-principle experiment was performed with 6-week old male Crl:CD(SD) rats exposed to diethylnitrosamine (DEN) for 28 consecutive days. One day later blood was collected for micronucleated reticulocyte (MN-RET) and Pig-a mutation assays, and liver tissue was obtained for micronucleated hepatocyte (MNHEP) scoring. MN-RET frequencies were not affected by DEN exposure, and mean Pig-a mutant cell frequencies were only slightly elevated. On the other hand, % MNHEP showed marked, dose-related increases (2.2, 7.2, and 9.1 mean fold-increase for 5, 10, 15 mg DEN/kg/day, respectively). Concurrent with MNHEP analyses, assessments of Ki-67-positive events and the proportion of 8n nuclei provided evidence for treatment-related changes to hepatocyte proliferation. Collectively, these results reinforce the importance of evaluating chemicals' genotoxic potential in liver in addition to hematopoietic cells, and suggest that several automated measurements can be successfully integrated into repeat-dose studies for higher efficiencies and better utilization of fewer animals.
Collapse
|
30
|
Long AS, Wills JW, Krolak D, Guo M, Dertinger SD, Arlt VM, White PA. Benchmark dose analyses of multiple genetic toxicity endpoints permit robust, cross-tissue comparisons of MutaMouse responses to orally delivered benzo[a]pyrene. Arch Toxicol 2018; 92:967-982. [PMID: 29177888 PMCID: PMC5818629 DOI: 10.1007/s00204-017-2099-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 10/17/2017] [Indexed: 12/14/2022]
Abstract
Genetic damage is a key event in tumorigenesis, and chemically induced genotoxic effects are a human health concern. Although genetic toxicity data have historically been interpreted using a qualitative screen-and-bin approach, there is increasing interest in quantitative analysis of genetic toxicity dose-response data. We demonstrate an emerging use of the benchmark dose (BMD)-approach for empirically ranking cross-tissue sensitivity. Using a model environmental carcinogen, we quantitatively examined responses for four genetic damage endpoints over an extended dose range, and conducted cross-tissue sensitivity rankings using BMD100 values and their 90% confidence intervals (CIs). MutaMouse specimens were orally exposed to 11 doses of benzo[a]pyrene. DNA adduct frequency and lacZ mutant frequency (MF) were measured in up to 8 tissues, and Pig-a MF and micronuclei (MN) were assessed in immature (RETs) and mature red blood cells (RBCs). The cross-tissue BMD pattern for lacZ MF is similar to that observed for DNA adducts, and is consistent with an oral route-of-exposure and differences in tissue-specific metabolism and proliferation. The lacZ MF BMDs were significantly correlated with the tissue-matched adduct BMDs, demonstrating a consistent adduct conversion rate across tissues. The BMD CIs, for both the Pig-a and the MN endpoints, overlapped for RETs and RBCs, suggesting comparable utility of both cell populations for protracted exposures. Examination of endpoint-specific response maxima illustrates the difficulty of comparing BMD values for a fixed benchmark response across endpoints. Overall, the BMD-approach permitted robust comparisons of responses across tissues/endpoints, which is valuable to our mechanistic understanding of how benzo[a]pyrene induces genetic damage.
Collapse
Affiliation(s)
- Alexandra S Long
- Mechanistic Studies Division, Environmental Health Science and Research Bureau, Health Canada, 50 Colombine Driveway, Tunney's Pasture, A/L 0803A, Ottawa, ON, K1A 0K9, Canada.
- Department of Biology, University of Ottawa, Ottawa, ON, Canada.
| | - John W Wills
- Mechanistic Studies Division, Environmental Health Science and Research Bureau, Health Canada, 50 Colombine Driveway, Tunney's Pasture, A/L 0803A, Ottawa, ON, K1A 0K9, Canada
- Department of Biology, University of Ottawa, Ottawa, ON, Canada
| | - Dorothy Krolak
- Mechanistic Studies Division, Environmental Health Science and Research Bureau, Health Canada, 50 Colombine Driveway, Tunney's Pasture, A/L 0803A, Ottawa, ON, K1A 0K9, Canada
| | - Matthew Guo
- Mechanistic Studies Division, Environmental Health Science and Research Bureau, Health Canada, 50 Colombine Driveway, Tunney's Pasture, A/L 0803A, Ottawa, ON, K1A 0K9, Canada
| | | | - Volker M Arlt
- Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment and Health, King's College London, London, UK
| | - Paul A White
- Mechanistic Studies Division, Environmental Health Science and Research Bureau, Health Canada, 50 Colombine Driveway, Tunney's Pasture, A/L 0803A, Ottawa, ON, K1A 0K9, Canada
- Department of Biology, University of Ottawa, Ottawa, ON, Canada
| |
Collapse
|
31
|
Wang Y, Revollo J, McKinzie P, Pearce MG, Dad A, Yucesoy B, Rosenfeldt H, Heflich RH, Dobrovolsky VN. Establishing a novel Pig-a gene mutation assay in L5178YTk +/- mouse lymphoma cells. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2018; 59:4-17. [PMID: 29098723 DOI: 10.1002/em.22152] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 10/02/2017] [Accepted: 10/04/2017] [Indexed: 06/07/2023]
Abstract
The X-linked Pig-a gene encodes an enzyme required for the biosynthesis of glycosyl phosphatidylinositol (GPI) anchors. Pig-a mutant cells fail to synthesize GPI and to express GPI-anchored protein markers (e.g., CD90) on their surface. Marker deficiency serves as a phenotypic indicator of Pig-a mutation in various in vivo assays. Here, we describe an in vitro Pig-a mutation assay in L5178YTk+/- mouse lymphoma cells, in which mutant-phenotype cells are measured by flow cytometry using a fluorescent anti-CD90 antibody. Increased frequencies of CD90-deficient mutants were detected in cells treated with benzo[a]pyrene (B[a]P), N-ethyl-N-nitrosourea (ENU), ethyl methanesulphonate, and 7,12-dimethylbenz[a]anthracene, with near maximum mutant frequencies measured eight days after treatment. The CD90 deficiency in mutant cells quantified by flow cytometry was shown to be due to loss of GPI anchors in a limiting-dilution cloning assay using proaerolysin selection. Individual CD90-deficient cells from cultures treated with ENU, B[a]P, and vehicle were sorted and clonally expanded for molecular analysis of their Pig-a gene. Pig-a mutations with agent-specific signatures were found in nearly all clones that developed from sorted CD90-deficient cells. These results indicate that a Pig-a mutation assay can be successfully conducted in L5178YTk+/- cells. The assay may be useful for mutagenicity screening of environmental agents as well as for testing hypotheses in vitro before committing to in vivo Pig-a assays. Environ. Mol. Mutagen. 59:4-17, 2018. Published 2017. This article is a US Government work and is in the public domain in the USA.
Collapse
Affiliation(s)
- Yiying Wang
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas
| | - Javier Revollo
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas
| | - Page McKinzie
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas
| | - Mason G Pearce
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas
| | - Azra Dad
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas
| | - Berran Yucesoy
- Division of Nonclinical Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Hans Rosenfeldt
- Division of Nonclinical Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Robert H Heflich
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas
| | - Vasily N Dobrovolsky
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas
| |
Collapse
|
32
|
Nicolette J, Murray J, Sonders P, Leroy B. A regenerative erythropoietic response does not increase the frequency of Pig-a mutant reticulocytes and erythrocytes in Sprague-Dawley rats. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2018; 59:91-95. [PMID: 29076186 DOI: 10.1002/em.22145] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 09/08/2017] [Accepted: 09/17/2017] [Indexed: 06/07/2023]
Abstract
The in vivo rodent Pig-a mutation assay is a sensitive test to identify exposure to mutagenic substances, and has been proposed as an assay for the identification of impurities for pharmaceuticals. Red blood cells (RBCs) and reticulocytes (RETs) are analyzed by flow cytometry after exposure to potentially mutagenic chemicals for cells deficient in the cell surface anchored protein CD59, representing mutation in the X-linked Pig-a gene. The full potential of the assay as well as its limitations are currently being explored. The current study investigated the effects of regenerative erythropoietic bone marrow responses on the frequency of Pig-a mutated reticulocytes (RETCD59- ) and erythrocytes (RBCCD59- ). We hypothesized that a robust regenerative erythropoietic response would not increase the basal frequency of RETCD59- or RBCCD59- cells. Two groups of six male Sprague-Dawley rats either had 2 mL of blood sampled each day via an indwelling catheter over a period of 5 days or were minimally sampled for hematology and used as controls. Blood was also then collected and evaluated 5, 18, and 49 days after the initial bleed period for the number of Pig-a mutant cells in either the RET or RBC population. Despite the expected decrease in hematocrit and the correlative increase in reticulocytes after bleeding, no increase in the number of Pig-a mutant cells was observed in male Sprague-Dawley rats that were bled for five consecutive days. These results indicate that changes in erythropoiesis and hematology parameters in rats appear to have no effect on the background levels of Pig-a mutated RETs and RBCs. Environ. Mol. Mutagen. 59:91-95, 2018. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- John Nicolette
- Pre-clinical safety, AbbVie, Inc, North Chicago, Illinois
| | - Joel Murray
- Pre-clinical safety, AbbVie, Inc, North Chicago, Illinois
| | - Paul Sonders
- Pre-clinical safety, AbbVie, Inc, North Chicago, Illinois
| | - Bruce Leroy
- Pre-clinical safety, AbbVie, Inc, North Chicago, Illinois
| |
Collapse
|
33
|
Avlasevich SL, Labash C, Torous DK, Bemis JC, MacGregor JT, Dertinger SD. In vivo pig-a and micronucleus study of the prototypical aneugen vinblastine sulfate. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2018; 59:30-37. [PMID: 28833575 PMCID: PMC5773054 DOI: 10.1002/em.22122] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 07/12/2017] [Accepted: 07/15/2017] [Indexed: 05/05/2023]
Abstract
The Pig-a assay is being used in regulatory studies to evaluate the potential of agents to induce somatic cell gene mutations and an OECD test guideline is under development. A working group involved with establishing the guideline recently noted that representative aneugenic agents had not been evaluated, and to help fill this data gap Pig-a mutant phenotype and micronucleated reticulocyte frequencies were measured in an integrated study design to assess the mutagenic and cytogenetic damage responses to vinblastine sulfate exposure. Male Sprague Dawley rats were treated for twenty-eight consecutive days with vinblastine dose levels from 0.0156 to 0.125 mg/kg/day. Micronucleated reticulocyte frequencies in peripheral blood were determined at Days 4 and 29, and mutant cell frequencies were determined at Days -4, 15, 29, and 46. Vinblastine affected reticulocyte frequencies, with reductions noted during the treatment phase and increases observed following cessation of treatment. Micronucleated reticulocyte frequencies were significantly elevated at Day 4 in the high dose group. Although a statistically significant increase in mutant reticulocyte frequencies were found for one dose group at a single time point (Day 46), it was not deemed biologically relevant because there was no analogous finding in mutant RBCs, it occurred at the lowest dose tested, and only 1 rat exceeded an upper bound tolerance interval established with historical negative control rats. Therefore, whereas micronucleus induction reflects vinblastine's well-established aneugenic effect on hematopoietic cells, the lack of a Pig-a response indicates that this tubulin-binding agent does not cause appreciable mutagenicity in this same cell type. Environ. Mol. Mutagen. 59:30-37, 2018. © 2017 Wiley Periodicals, Inc.
Collapse
|
34
|
Graupner A, Eide DM, Brede DA, Ellender M, Lindbo Hansen E, Oughton DH, Bouffler SD, Brunborg G, Olsen AK. Genotoxic effects of high dose rate X-ray and low dose rate gamma radiation in Apc Min/+ mice. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2017; 58:560-569. [PMID: 28856770 PMCID: PMC5656900 DOI: 10.1002/em.22121] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Revised: 07/01/2017] [Accepted: 07/05/2017] [Indexed: 06/07/2023]
Abstract
Risk estimates for radiation-induced cancer in humans are based on epidemiological data largely drawn from the Japanese atomic bomb survivor studies, which received an acute high dose rate (HDR) ionising radiation. Limited knowledge exists about the effects of chronic low dose rate (LDR) exposure, particularly with respect to the application of the dose and dose rate effectiveness factor. As part of a study to investigate the development of colon cancer following chronic LDR vs. acute HDR radiation, this study presents the results of genotoxic effects in blood of exposed mice. CBAB6 F1 Apc+/+ (wild type) and ApcMin/+ mice were chronically exposed to estimated whole body absorbed doses of 1.7 or 3.2 Gy 60 Co-γ-rays at a LDR (2.2 mGy h-1 ) or acutely exposed to 2.6 Gy HDR X-rays (1.3 Gy min-1 ). Genotoxic endpoints assessed in blood included chromosomal damage (flow cytometry based micronuclei (MN) assay), mutation analyses (Pig-a gene mutation assay), and levels of DNA lesions (Comet assay, single-strand breaks (ssb), alkali labile sites (als), oxidized DNA bases). Ionising radiation (ca. 3 Gy) induced genotoxic effects dependent on the dose rate. Chromosomal aberrations (MN assay) increased 3- and 10-fold after chronic LDR and acute HDR, respectively. Phenotypic mutation frequencies as well as DNA lesions (ssb/als) were modulated after acute HDR but not after chronic LDR. The ApcMin/+ genotype did not influence the outcome in any of the investigated endpoints. The results herein will add to the scant data available on genotoxic effects following chronic LDR of ionising radiation. Environ. Mol. Mutagen. 58:560-569, 2017. © 2017 The Authors Environmental and Molecular Mutagenesis published by Wiley Periodicals, Inc. on behalf of Environmental Mutagen Society.
Collapse
Affiliation(s)
- Anne Graupner
- Department of Molecular BiologyNorwegian Institute of Public HealthOslo0403Norway
- Centre for Environmental Radioactivity (CoE CERAD)Ås 1432Norway
| | - Dag M. Eide
- Centre for Environmental Radioactivity (CoE CERAD)Ås 1432Norway
- Department of Toxicology and Risk AssessmentNorwegian Institute of Public HealthOslo0403Norway
| | - Dag A. Brede
- Centre for Environmental Radioactivity (CoE CERAD)Ås 1432Norway
- Department of Environmental SciencesNorwegian University of Life SciencesÅs 1432Norway
| | - Michele Ellender
- Radiation Effects DepartmentCentre for Radiation, Chemical and Environmental Hazards, Public Health EnglandChiltonDidcotOX11 0RQEngland
| | - Elisabeth Lindbo Hansen
- Centre for Environmental Radioactivity (CoE CERAD)Ås 1432Norway
- Department of ResearchNorwegian Radiation Protection AuthorityØsterås1361Norway
| | - Deborah H. Oughton
- Centre for Environmental Radioactivity (CoE CERAD)Ås 1432Norway
- Department of Environmental SciencesNorwegian University of Life SciencesÅs 1432Norway
| | - Simon D. Bouffler
- Radiation Effects DepartmentCentre for Radiation, Chemical and Environmental Hazards, Public Health EnglandChiltonDidcotOX11 0RQEngland
| | - Gunnar Brunborg
- Department of Molecular BiologyNorwegian Institute of Public HealthOslo0403Norway
- Centre for Environmental Radioactivity (CoE CERAD)Ås 1432Norway
| | - Ann Karin Olsen
- Department of Molecular BiologyNorwegian Institute of Public HealthOslo0403Norway
- Centre for Environmental Radioactivity (CoE CERAD)Ås 1432Norway
| |
Collapse
|
35
|
Ji Z, LeBaron MJ. Applying the erythrocyte Pig-a assay concept to rat epididymal sperm for germ cell mutagenicity evaluation. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2017; 58:485-493. [PMID: 28714084 DOI: 10.1002/em.22109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2017] [Revised: 05/18/2017] [Accepted: 05/18/2017] [Indexed: 06/07/2023]
Abstract
The Pig-a assay, a recently developed in vivo somatic gene mutation assay, is based on the identification of mutant erythrocytes that have an altered repertoire of glycosylphosphatidylinositol (GPI)-anchored cell surface markers. We hypothesized that the erythrocyte Pig-a assay concept could be applied to rat cauda epididymal spermatozoa (sperm) for germ cell mutagenicity evaluation. We used GPI-anchored CD59 as the Pig-a mutation marker and examined the frequency of CD59-negative sperm using flow cytometry. A reconstruction experiment that spiked un-labeled sperm (mutant-mimic) into labeled sperm at specific ratios yielded good agreement between the detected and expected frequencies of mutant-mimic sperm, demonstrating the analytical ability for CD59-negative sperm detection. Furthermore, this methodology was assessed in F344/DuCrl rats administered N-ethyl-N-nitrosourea (ENU), a prototypical mutagen, or clofibrate, a lipid-lowering drug. Rats treated with 1, 10, or 20 mg/kg body weight/day (mkd) ENU via daily oral garage for five consecutive days showed a dose-dependent increase in the frequency of CD59-negative sperm on study day 63 (i.e., 58 days after the last ENU dose). This ENU dosing regimen also increased the frequency of CD59-negative erythrocytes. In rats treated with 300 mkd clofibrate via daily oral garage for consecutive 28 days, no treatment-related changes were detected in the frequency of CD59-negative sperm on study day 85 (i.e., 57 days after the last dose) or in the frequency of CD59-negative erythrocytes on study day 29. In conclusion, these data suggest that the epidiymal sperm Pig-a assay in rats is a promising method for evaluating germ cell mutagenicity. Environ. Mol. Mutagen. 58:485-493, 2017. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Zhiying Ji
- Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan, 48674
| | - Matthew J LeBaron
- Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan, 48674
| |
Collapse
|
36
|
No cancer predisposition or increased spontaneous mutation frequencies in NEIL DNA glycosylases-deficient mice. Sci Rep 2017; 7:4384. [PMID: 28663564 PMCID: PMC5491499 DOI: 10.1038/s41598-017-04472-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Accepted: 05/16/2017] [Indexed: 02/07/2023] Open
Abstract
Base excision repair (BER) is a major pathway for removal of DNA base lesions and maintenance of genomic stability, which is essential in cancer prevention. DNA glycosylases recognize and remove specific lesions in the first step of BER. The existence of a number of these enzymes with overlapping substrate specificities has been thought to be the reason why single knock-out models of individual DNA glycosylases are not cancer prone. In this work we have characterized DNA glycosylases NEIL1 and NEIL2 (Neil1−/−/Neil2−/−) double and NEIL1, NEIL2 and NEIL3 (Neil1−/−/Neil2−/−/Neil3−/−) triple knock-out mouse models. Unexpectedly, our results show that these mice are not prone to cancer and have no elevated mutation frequencies under normal physiological conditions. Moreover, telomere length is not affected and there was no accumulation of oxidative DNA damage compared to wild-type mice. These results strengthen the hypothesis that the NEIL enzymes are not simply back-up enzymes for each other but enzymes that have distinct functions beyond canonical repair.
Collapse
|
37
|
Olsen AK, Dertinger SD, Krüger CT, Eide DM, Instanes C, Brunborg G, Hartwig A, Graupner A. The Pig-a Gene Mutation Assay in Mice and Human Cells: A Review. Basic Clin Pharmacol Toxicol 2017; 121 Suppl 3:78-92. [PMID: 28481423 DOI: 10.1111/bcpt.12806] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 05/01/2017] [Indexed: 01/08/2023]
Abstract
This MiniReview describes the principle of mutation assays based on the endogenous Pig-a gene and summarizes results for two species of toxicological interest, mice and human beings. The work summarized here largely avoids rat-based studies, as are summarized elsewhere. The Pig-a gene mutation assay has emerged as a valuable tool for quantifying in vivo and in vitro mutational events. The Pig-a locus is located at the X-chromosome, giving the advantage that one inactivated allele can give rise to a mutated phenotype, detectable by multicolour flow cytometry. For in vivo studies, only minute blood volumes are required, making it easily incorporated into ongoing studies or experiments with limited biological materials. Low blood volumes also allow individuals to serve as their own controls, providing temporal information of the mutagenic process, and/or outcome of intervention. These characteristics make it a promising exposure marker. To date, the Pig-a gene mutation assay has been most commonly performed in rats, while reports regarding its usefulness in other species are accumulating. Besides its applicability to in vivo studies, it holds promise for genotoxicity testing using cultured cells, as shown in recent studies. In addition to safety assessment roles, it is becoming a valuable tool in basic research to identify mutagenic effects of different interventions or to understand implications of various gene defects by investigating modified mouse models or cell systems. Human blood-based assays are also being developed that may be able to identify genotoxic environmental exposures, treatment- and lifestyle-related factors or endogenous host factors that contribute to mutagenesis.
Collapse
Affiliation(s)
- Ann-Karin Olsen
- Department of Molecular Biology, The Norwegian Institute of Public Health, Oslo, Norway.,Centre for Environmental Radioactivity (CERAD CoE), Norway
| | | | - Christopher T Krüger
- Food Chemistry and Toxicology, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany
| | - Dag M Eide
- Centre for Environmental Radioactivity (CERAD CoE), Norway.,Department of Toxicology and Risk, The Norwegian Institute of Public Health, Oslo, Norway
| | - Christine Instanes
- Department of Molecular Biology, The Norwegian Institute of Public Health, Oslo, Norway.,Centre for Environmental Radioactivity (CERAD CoE), Norway
| | - Gunnar Brunborg
- Department of Molecular Biology, The Norwegian Institute of Public Health, Oslo, Norway.,Centre for Environmental Radioactivity (CERAD CoE), Norway
| | - Andrea Hartwig
- Food Chemistry and Toxicology, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany
| | - Anne Graupner
- Department of Molecular Biology, The Norwegian Institute of Public Health, Oslo, Norway.,Centre for Environmental Radioactivity (CERAD CoE), Norway
| |
Collapse
|
38
|
Castel P, Carcopino X, Robert S, Bonetto R, Cowen D, Orsiere T. [The PIG-A gene as a new biomarker of mutagenesis: proof of concept and technical specifications]. Med Sci (Paris) 2017; 33:432-439. [PMID: 28497740 DOI: 10.1051/medsci/20173304014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Gene mutations are not directly detected by current genotoxicity assays and most of them need a cell culture step. The whole blood PIG-A assay consists in the detection of the mutation frequency within the PIG-A sentinel gene by identification of glycosyl-phosphatidyl-inositol (GPI-) deficient cells. PIG-A mutated/GPI-deficient cells can be detected by flow cytometry as they no longer express surface fluorescence for GPI-linked markers. The last researches have focused on cell enrichment techniques leading to increased throughput and sensitivity. The results of this new and promising biomarker of mutagenesis, performed in humans or rodents, are now available within 2 hours after blood collection.
Collapse
Affiliation(s)
- Pierre Castel
- Institut Méditerranéen de Biodiversité et d'Écologie (IMBE), équipe Biogénotoxicologie, Santé Humaine et Environnement, Aix-Marseille Université (AMU), CNRS, IRD, Avignon Université, Faculté de Médecine de Marseille, 27, boulevard Jean Moulin, 13005 Marseille, France
| | - Xavier Carcopino
- Institut Méditerranéen de Biodiversité et d'Écologie (IMBE), équipe Biogénotoxicologie, Santé Humaine et Environnement, Aix-Marseille Université (AMU), CNRS, IRD, Avignon Université, Faculté de Médecine de Marseille, 27, boulevard Jean Moulin, 13005 Marseille, France - Département d'obstétrique et de gynécologie, Hôpital Nord, APHM, Aix-Marseille Université (AMU), Marseille, France
| | - Stéphane Robert
- Vascular Research Center of Marseille, Aix-Marseille Université (AMU), UMR Inserm 1076, Faculté de Pharmacie, Marseille, France
| | - Rémi Bonetto
- Département de Radiothérapie, Hôpital Nord, APHM, Aix-Marseille Université (AMU), Marseille, France
| | - Didier Cowen
- Département de Radiothérapie, Hôpital Nord, APHM, Aix-Marseille Université (AMU), Marseille, France
| | - Thierry Orsiere
- Institut Méditerranéen de Biodiversité et d'Écologie (IMBE), équipe Biogénotoxicologie, Santé Humaine et Environnement, Aix-Marseille Université (AMU), CNRS, IRD, Avignon Université, Faculté de Médecine de Marseille, 27, boulevard Jean Moulin, 13005 Marseille, France
| |
Collapse
|
39
|
Rees BJ, Tate M, Lynch AM, Thornton CA, Jenkins GJ, Walmsley RM, Johnson GE. Development of an in vitro PIG-A gene mutation assay in human cells. Mutagenesis 2017; 32:283-297. [PMID: 28057708 PMCID: PMC5907909 DOI: 10.1093/mutage/gew059] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Accepted: 11/15/2016] [Indexed: 11/12/2022] Open
Abstract
Mutagens can be carcinogens, and traditionally, they have been identified in vitro using the Salmonella 'Ames' reverse mutation assay. However, prokaryotic DNA packaging, replication and repair systems are mechanistically very different to those in the humans we inevitably seek to protect. Therefore, for many years, mammalian cell line genotoxicity assays that can detect eukaryotic mutagens as well as clastogens and aneugens have been used. The apparent lack of specificity in these largely rodent systems, due partly to their mutant p53 status, has contributed to the use of animal studies to resolve data conflicts. Recently, silencing mutations at the PIG-A locus have been demonstrated to prevent glycophosphatidylinositol (GPI) anchor synthesis and consequentially result in loss of GPI-anchored proteins from the cell's extracellular surface. The successful exploitation of this mutant phenotype in animal studies has triggered interest in the development of an analogous in vitro PIG-A mutation screening assay. This article describes the development of a robust assay design using metabolically active human cells. The assay includes viability and cell membrane integrity assessment and conforms to the future ideas of the 21st-century toxicology testing.
Collapse
Affiliation(s)
- Benjamin J Rees
- Institute of Life Science, Swansea University Medical School, Singleton Park, Swansea, UK
| | - Matthew Tate
- Gentronix Ltd BioHub at Alderley Park, Alderley Edge, Cheshire, UK
| | | | - Catherine A Thornton
- Institute of Life Science, Swansea University Medical School, Singleton Park, Swansea, UK
| | - Gareth J Jenkins
- Institute of Life Science, Swansea University Medical School, Singleton Park, Swansea, UK
| | - Richard M Walmsley
- Gentronix Ltd BioHub at Alderley Park, Alderley Edge, Cheshire, UK
- Faculty of Life Sciences, University of Manchester, Manchester, UK
| | - George E Johnson
- Institute of Life Science, Swansea University Medical School, Singleton Park, Swansea, UK
| |
Collapse
|
40
|
Dobrovolsky VN, Revollo J, Petibone DM, Heflich RH. In Vivo Rat T-Lymphocyte Pig-a Assay: Detection and Expansion of Cells Deficient in the GPI-Anchored CD48 Surface Marker for Analysis of Mutation in the Endogenous Pig-a Gene. Methods Mol Biol 2017; 1641:143-160. [PMID: 28748462 DOI: 10.1007/978-1-4939-7172-5_7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The Pig-a assay is being developed as an in vivo gene mutation assay for regulatory safety assessments. The assay is based on detecting mutation in the endogenous Pig-a gene of treated rats by using flow cytometry to measure changes in cell surface markers of peripheral blood cells. Here we present a methodology for demonstrating that phenotypically mutant rat T-cells identified by flow cytometry contain mutations in the Pig-a gene, an important step for validating the assay. In our approach, the mutant phenotype T-cells are sorted into individual wells of 96-well plates and expanded into clones. Subsequent sequencing of genomic DNA from the expanded clones confirms that the Pig-a assay detects exactly what it claims to detect-cells with mutations in the endogenous Pig-a gene. In addition, determining the spectra of Pig-a mutations provides information for better understanding the mutational mechanism of compounds of interest. Our methodology of combining phenotypic antibody labeling, magnetic enrichment, sorting, and single-cell clonal expansion can be used in genotoxicity/mutagenicity studies and in other general immunotoxicology research requiring identification, isolation, and expansion of extremely rare subpopulations of T-cells.
Collapse
Affiliation(s)
- Vasily N Dobrovolsky
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., HFT-120, Jefferson, AR, 72079, USA.
| | - Javier Revollo
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., HFT-120, Jefferson, AR, 72079, USA
| | - Dayton M Petibone
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., HFT-120, Jefferson, AR, 72079, USA
| | - Robert H Heflich
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., HFT-120, Jefferson, AR, 72079, USA
| |
Collapse
|
41
|
Raschke M, Igl BW, Kenny J, Collins J, Dertinger SD, Labash C, Bhalli JA, Tebbe CCM, McNeil KM, Sutter A. In Vivo Pig-a gene mutation assay: Guidance for 3Rs-friendly implementation. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2016; 57:678-686. [PMID: 27770464 DOI: 10.1002/em.22060] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Accepted: 09/15/2016] [Indexed: 06/06/2023]
Abstract
The rodent Pig-a assay is an in vivo method for the detection of gene mutation, where lack of glycosylphosphatidylinositol-anchored proteins on the surface of circulating red blood cells (RBCs) serves as a reporter for Pig-a gene mutation. In the case of rats, the frequency of mutant phenotype RBCs is measured via fluorescent anti-CD59 antibodies and flow cytometry. The Pig-a assay meets the growing expectations for novel approaches in animal experimentation not only focusing on the scientific value of the assay but also on animal welfare aspects (3Rs principles), for example, amenable to integration into pivotal rodent 28-day general toxicology studies. However, as recommended in the Organisation for Economic Co-operation and Development Test Guidelines for genotoxicity testing, laboratories are expected to demonstrate their proficiency. While this has historically involved the extensive use of animals, here we describe an alternative approach based on a series of blood dilutions covering a range of mutant frequencies. The experiments described herein utilized either non-fluorescent anti-CD59 antibodies to provide elevated numbers of mutant-like cells, or a low volume blood sample from a single N-ethyl-N-nitrosourea treated animal. Results from these so-called reconstruction experiments from four independent laboratories showed good overall precision (correlation coefficients: 0.9979-0.9999) and accuracy (estimated slope: 0.71-1.09) of mutant cell scoring, which was further confirmed by Bland-Altman analysis. These data strongly support the use of reconstruction experiments for training purposes and demonstrating laboratory proficiency with very few animals, an ideal situation given the typically conflicting goals of demonstrating laboratory proficiency and reducing the use of animals. Environ. Mol. Mutagen. 57:678-686, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Marian Raschke
- Bayer Pharma AG, Muellerstrasse 178, Berlin, 13353, Germany
| | - Bernd-W Igl
- Bayer Pharma AG, Muellerstrasse 178, Berlin, 13353, Germany
| | - Julia Kenny
- GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom
| | - Joanne Collins
- GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom
| | | | - Carson Labash
- Litron Laboratories, 3500 Winton Place, Rochester, New York, 14623
| | - Javed A Bhalli
- Covance Laboratories Inc, 671 S. Meridian Rd, Greenfield, Indiana, 46140
| | - Cameron C M Tebbe
- Covance Laboratories Inc, 671 S. Meridian Rd, Greenfield, Indiana, 46140
| | - Kylie M McNeil
- Covance Laboratories Inc, 671 S. Meridian Rd, Greenfield, Indiana, 46140
| | - Andreas Sutter
- Bayer Pharma AG, Muellerstrasse 178, Berlin, 13353, Germany
| |
Collapse
|
42
|
Wickliffe JK, Dertinger SD, Torous DK, Avlasevich SL, Simon-Friedt BR, Wilson MJ. Diet-induced obesity increases the frequency of Pig-a mutant erythrocytes in male C57BL/6J mice. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2016; 57:668-677. [PMID: 27739633 PMCID: PMC5118159 DOI: 10.1002/em.22058] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 09/12/2016] [Accepted: 09/14/2016] [Indexed: 05/10/2023]
Abstract
Obesity increases the risk of a number of chronic diseases in humans including several cancers. Biological mechanisms responsible for such increased risks are not well understood at present. Increases in systemic inflammation and oxidative stress, endogenous production of mutagenic metabolites, altered signaling in proliferative pathways, and increased sensitivity to exogenous mutagens and carcinogens are some of the potential contributing factors. We hypothesize that obesity creates an endogenously mutagenic environment in addition to increasing the sensitivity to environmental mutagens. To test this hypothesis, we examined two in vivo genotoxicity endpoints. Pig-a mutant frequencies and micronucleus frequencies were determined in blood cells in two independent experiments in 30-week old male mice reared on either a high-fat diet (60% calories from fat) that exhibit an obese phenotype or a normal-fat diet (10% calories from fat) that do not exhibit an obese phenotype. Mice were assayed again at 52 weeks of age in one of the experiments. N-ethyl-N-nitrosourea (ENU) was used as a positive mutation control in one experiment. ENU induced a robust Pig-a mutant and micronucleus response in both phenotypes. Obese, otherwise untreated mice, did not differ from non-obese mice with respect to Pig-a mutant frequencies in reticulocytes or micronucleus frequencies. However, such mice, had significantly higher and sustained Pig-a mutant frequencies (increased 2.5-3.7-fold, p < 0.02) in erythrocytes as compared to non-obese mice (based on measurements collected at 30 weeks or 30 and 52 weeks of age). This suggests that obesity, in the absence of exposure to an exogenous mutagen, is itself mutagenic. Environ. Mol. Mutagen. 57:668-677, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Jeffrey K. Wickliffe
- Department of Global Environmental Health Sciences, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112 USA
| | | | | | | | - Bridget R. Simon-Friedt
- Department of Global Environmental Health Sciences, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112 USA
| | - Mark J. Wilson
- Department of Global Environmental Health Sciences, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112 USA
| |
Collapse
|
43
|
Kimoto T, Horibata K, Miura D, Chikura S, Okada Y, Ukai A, Itoh S, Nakayama S, Sanada H, Koyama N, Muto S, Uno Y, Yamamoto M, Suzuki Y, Fukuda T, Goto K, Wada K, Kyoya T, Shigano M, Takasawa H, Hamada S, Adachi H, Uematsu Y, Tsutsumi E, Hori H, Kikuzuki R, Ogiwara Y, Yoshida I, Maeda A, Narumi K, Fujiishi Y, Morita T, Yamada M, Honma M. The PIGRET assay, a method for measuring Pig-a gene mutation in reticulocytes, is reliable as a short-term in vivo genotoxicity test: Summary of the MMS/JEMS-collaborative study across 16 laboratories using 24 chemicals. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2016; 811:3-15. [DOI: 10.1016/j.mrgentox.2016.10.003] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 10/18/2016] [Indexed: 10/20/2022]
|
44
|
Chikura S, Okada Y, Kimoto T, Kaneko H, Miura D, Kasahara Y. The rat Pig-a assay using an erythroid HIS49 antibody in a single dose study of isopropyl p-toluenesulfonate. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2016; 811:110-116. [DOI: 10.1016/j.mrgentox.2016.04.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Accepted: 04/13/2016] [Indexed: 10/21/2022]
|
45
|
Muto S, Yamada K, Kato T, Ando M, Inoue Y, Iwase Y, Uno Y. Evaluation of the mutagenicity of alkylating agents, methylnitrosourea and temozolomide, using the rat Pig-a assay with total red blood cells or reticulocytes. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2016; 811:117-122. [DOI: 10.1016/j.mrgentox.2016.01.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Accepted: 01/20/2016] [Indexed: 01/24/2023]
|
46
|
Chikura S, Okada Y, Kimoto T, Kaneko H, Miura D, Kasahara Y. Report on the rat Pig-a assay using an anti-rat erythroid marker HIS49 antibody in a single dose study of 1,2-dimethylhydrazine. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2016; 811:21-28. [DOI: 10.1016/j.mrgentox.2016.02.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Accepted: 02/29/2016] [Indexed: 10/21/2022]
|
47
|
Evaluation of mutagenicity of acrylamide using RBC Pig-a and PIGRET assays by single peroral dose in rats. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2016; 811:54-59. [DOI: 10.1016/j.mrgentox.2015.12.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Accepted: 12/16/2015] [Indexed: 11/22/2022]
|
48
|
Graupner A, Eide DM, Instanes C, Andersen JM, Brede DA, Dertinger SD, Lind OC, Brandt-Kjelsen A, Bjerke H, Salbu B, Oughton D, Brunborg G, Olsen AK. Gamma radiation at a human relevant low dose rate is genotoxic in mice. Sci Rep 2016; 6:32977. [PMID: 27596356 PMCID: PMC5011728 DOI: 10.1038/srep32977] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Accepted: 08/10/2016] [Indexed: 12/16/2022] Open
Abstract
Even today, 70 years after Hiroshima and accidents like in Chernobyl and Fukushima, we still have limited knowledge about the health effects of low dose rate (LDR) radiation. Despite their human relevance after occupational and accidental exposure, only few animal studies on the genotoxic effects of chronic LDR radiation have been performed. Selenium (Se) is involved in oxidative stress defence, protecting DNA and other biomolecules from reactive oxygen species (ROS). It is hypothesised that Se deficiency, as it occurs in several parts of the world, may aggravate harmful effects of ROS-inducing stressors such as ionising radiation. We performed a study in the newly established LDR-facility Figaro on the combined effects of Se deprivation and LDR γ exposure in DNA repair knockout mice (Ogg1−/−) and control animals (Ogg1+/−). Genotoxic effects were seen after continuous radiation (1.4 mGy/h) for 45 days. Chromosomal damage (micronucleus), phenotypic mutations (Pig-a gene mutation of RBCCD24−) and DNA lesions (single strand breaks/alkali labile sites) were significantly increased in blood cells of irradiated animals, covering three types of genotoxic activity. This study demonstrates that chronic LDR γ radiation is genotoxic in an exposure scenario realistic for humans, supporting the hypothesis that even LDR γ radiation may induce cancer.
Collapse
Affiliation(s)
- Anne Graupner
- Department of Chemicals and Radiation, Norwegian Institute of Public Health, Oslo 0403, Norway.,Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Dag M Eide
- Department of Chemicals and Radiation, Norwegian Institute of Public Health, Oslo 0403, Norway.,Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Christine Instanes
- Department of Chemicals and Radiation, Norwegian Institute of Public Health, Oslo 0403, Norway.,Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Jill M Andersen
- Department of Chemicals and Radiation, Norwegian Institute of Public Health, Oslo 0403, Norway.,Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Dag A Brede
- Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway.,Department of Environmental Sciences (IMV), Norwegian University of Life Sciences (NMBU), Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | | | - Ole C Lind
- Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway.,Department of Environmental Sciences (IMV), Norwegian University of Life Sciences (NMBU), Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Anicke Brandt-Kjelsen
- Department of Environmental Sciences (IMV), Norwegian University of Life Sciences (NMBU), Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Hans Bjerke
- Department of Monitoring and Research, Norwegian Radiation Protection Authority, Østerås 1332, Norway
| | - Brit Salbu
- Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway.,Department of Environmental Sciences (IMV), Norwegian University of Life Sciences (NMBU), Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Deborah Oughton
- Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway.,Department of Environmental Sciences (IMV), Norwegian University of Life Sciences (NMBU), Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Gunnar Brunborg
- Department of Chemicals and Radiation, Norwegian Institute of Public Health, Oslo 0403, Norway.,Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| | - Ann K Olsen
- Department of Chemicals and Radiation, Norwegian Institute of Public Health, Oslo 0403, Norway.,Centre for Environmental Radioactivity (CoE CERAD), Ås 1432, Norway
| |
Collapse
|
49
|
Wills JW, Long AS, Johnson GE, Bemis JC, Dertinger SD, Slob W, White PA. Empirical analysis of BMD metrics in genetic toxicology part II: in vivo potency comparisons to promote reductions in the use of experimental animals for genetic toxicity assessment. Mutagenesis 2016; 31:265-75. [PMID: 26984301 DOI: 10.1093/mutage/gew009] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Genotoxicity tests have traditionally been used only for hazard identification, with qualitative dichotomous groupings being used to identify compounds that have the capacity to induce mutations and/or cytogenetic alterations. However, there is an increasing interest in employing quantitative analysis of in vivo dose-response data to derive point of departure (PoD) metrics that can be used to establish human exposure limits or margins of exposure (MOEs), thereby supporting human health risk assessments and regulatory decisions. This work is an extension of our companion article on in vitro dose-response analyses and outlines how the combined benchmark dose (BMD) approach across included covariates can be used to improve the analyses and interpretation of in vivo genetic toxicity dose-response data. Using the BMD-covariate approach, we show that empirical comparisons of micronucleus frequency dose-response data across multiple studies justifies dataset merging, with subsequent analyses improving the precision of BMD estimates and permitting attendant potency ranking of seven clastogens. Similarly, empirical comparisons of Pig-a mutant phenotype frequency data collected in males and females justified dataset merging across sex. This permitted more effective scrutiny regarding the effect of post-exposure sampling time on the mutagenicity of N-ethyl-N-nitrosourea observed in reticulocytes and erythrocytes in the Pig-a assay. The BMD-covariate approach revealed tissue-specific differences in the induction of lacZ transgene mutations in Muta™Mouse specimens exposed to benzo[a]pyrene (BaP), with the results permitting the formulation of mechanistic hypotheses regarding the observed potency ranking. Lastly, we illustrate how historical dose-response data for assessments that examined numerous doses (i.e. induced lacZ mutant frequency (MF) across 10 doses of BaP) can be used to improve the precision of BMDs derived from datasets with far fewer doses (i.e. lacZ MF for 3 doses of dibenz[a,h]anthracene). Collectively, the presented examples illustrate how innovative use of the BMD approach can permit refinement of the use of in vivo data; improving the efficacy of experimental animal use in genetic toxicology without sacrificing PoD precision.
Collapse
Affiliation(s)
- John W Wills
- Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario K1A 0K9, Canada,
| | - Alexandra S Long
- Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario K1A 0K9, Canada
| | - George E Johnson
- Swansea University Medical School, Institute of Life Science, Swansea SA2 8PP, UK
| | | | | | - Wout Slob
- National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands
| | - Paul A White
- Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario K1A 0K9, Canada,
| |
Collapse
|
50
|
Moderate malnutrition in rats induces somatic gene mutations. Mutat Res 2016; 789:26-32. [PMID: 26994962 DOI: 10.1016/j.mrfmmm.2016.01.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 01/07/2016] [Accepted: 01/30/2016] [Indexed: 11/21/2022]
Abstract
The relationship between malnutrition and genetic damage has been widely studied in human and animal models, leading to the observation that interactions between genotoxic exposure and micronutrient status appear to affect genomic stability. A new assay has been developed that uses the phosphatidylinositol glycan class A gene (Pig-a) as a reporter for measuring in vivo gene mutation. The Pig-a assay can be employed to evaluate mutant frequencies (MFs) in peripheral blood reticulocytes (RETs) and erythrocytes (RBCs) using flow cytometry. In the present study, we assessed the effects of malnutrition on mutagenic susceptibility by exposing undernourished (UN) and well-nourished (WN) rats to N-ethyl-N-nitrosourea (ENU) and measuring Pig-a MFs. Two week-old UN and WN male Han-Wistar rats were treated daily with 0, 20, or 40mg/kg ENU for 3 consecutive days. Blood was collected from the tail vein one day before ENU treatment (Day-1) and after ENU administration on Days 7, 14, 21, 28, 35, 42, 49, 56 and 63. Pig-a MFs were measured in RETs and RBCs as the RET(CD59-) and RBC(CD59-) frequencies. In the vehicle control groups, the frequencies of mutant RETs and RBCs were significantly higher in UN rats compared with WN rats at all sampling times. The ENU treatments increased RET and RBC MFs starting at Day 7. Although ENU-induced Pig-a MFs were consistently lower in UN rats than in WN rats, these differences were not significant. To understand these responses, further studies should use other mutagens and nucleated surrogate cells and examine the types of mutations induced in UN and WN rats.
Collapse
|